BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Sarcoma clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for sarcoma: 151 (124 sponsors; 20 newly posted in the last 180 days, 12 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 4.6, rank 88 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 4, Phase 1 57, Phase 2 64, Phase 3 8, Phase 4 1, N/A 17.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 3 | NA 1, P3 1, P2 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 3 | P2 2, P3 1 | 0 | 0 |
| Advenchen Laboratories, LLC | 1 | P3 1 | 0 | 0 |
| Intensity Therapeutics, Inc. INTS | 1 | P3 1 | 0 | 0 |
| Ionis Pharmaceuticals, Inc. IONS | 1 | P3 1 | 0 | 0 |
| PharmaMar | 1 | P3 1 | 0 | 0 |
| Sinocelltech Ltd. | 1 | P3 1 | 0 | 0 |
| Takara Bio Inc. | 1 | P3 1 | 0 | 0 |
| Alpha Tau Medical LTD. DRTS | 4 | NA 4 | 0 | 3 |
| USWM CT, LLC | 4 | P2 3, P1 1 | 0 | 0 |
| Eli Lilly and Company LLY | 3 | P2 2, P1 1 | 0 | 0 |
| Hoffmann-La Roche | 3 | P1 2, P2 1 | 1 | 0 |
| Novartis Pharmaceuticals NVS | 3 | NA 1, P1 2 | 1 | 0 |
| Advenchen Pharmaceuticals, LLC. new entrant | 2 | P2 2 | 2 | 0 |
| Amgen AMGN | 2 | P1 2 | 0 | 1 |
| Ascentage Pharma Group Inc. AAPG | 2 | P2 2 | 0 | 0 |
| Bristol-Myers Squibb BMY | 2 | P1 1, P2 1 | 0 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2 | P2 2 | 0 | 0 |
| GlaxoSmithKline | 2 | P2 2 | 1 | 0 |
| Hansoh BioMedical R&D Company | 2 | P2 1, P1 1 | 0 | 1 |
| Hexin (Suzhou) Pharmaceutical Technology Co., Ltd new entrant | 2 | P1 1, P2 1 | 2 | 2 |
| Lantheus Medical Imaging LNTH | 2 | P2 2 | 0 | 0 |
| MedPacto, Inc. | 2 | P2 1, NA 1 | 1 | 1 |
| Turning Point Therapeutics, Inc. TPB | 2 | P2 2 | 0 | 0 |
| Actithera INC. new entrant | 1 | P2 1 | 1 | 0 |
New-entrant sponsors: Advenchen Pharmaceuticals, LLC., Hexin (Suzhou) Pharmaceutical Technology Co., Ltd, Actithera INC..
Recently stopped trials
- NCT06341712 Ipsen - terminated: The sponsor has decided to terminate the CabOSTar study due to ongoing recruitment challenges Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
- NCT02875548 Epizyme, Inc. - terminated: Sponsor decision; no additional participant enrollment was anticipated. A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazem
- NCT06566092 Iovance Biotherapeutics, Inc. - terminated: After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits. Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- NCT07052383 Tcelltech Inc. - suspended: Data update in progress. Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
- NCT01168791 Alaunos Therapeutics - terminated: Primary endpoint (PFS) not met at the final analysis; sponsor decided to stop the study before the planned final overall survival analysis. Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma
- NCT00718484 Alaunos Therapeutics - terminated: Sponsor stopped enrollment at 67 of about 100 planned participants after an unplanned interim analysis confirmed the primary PFS endpoint ha A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
- NCT05826600 iOmx Therapeutics AG - terminated: Study terminated as part of strategic considerations and not based on safety concerns. A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
- NCT06008483 QSAM Therapeutics, Inc. - terminated: Change in development program indication A Dose Finding Study to Treat Bone Tumor(s)
- NCT05712694 Polaris Group - terminated: Lack of Efficacy, no safety concern. Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
- NCT05130255 Y-mAbs Therapeutics - terminated: Decision by Sponsor GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
- NCT05949632 Incyte Corporation - terminated: This was a strategic business decision. There were no safety concerns contributing to this decision. A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-01 est. | P2 | EpicentRx, Inc. | NCT04673942 A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Solid Tumor, Adult; Cancer; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Chondrosarcoma | active not recruiting | 140 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P2 | Hexin (Suzhou) Pharmaceutical Technology Co., Ltd | NCT07920835 A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging | Soft Tissue Sarcoma | recruiting | 60 |
| 2027-01 est. | P2 | QBiotics Group Limited | NCT05755113 A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | Soft Tissue Sarcoma | recruiting | 40 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2027-04-14 | PDUFA date (company-disclosed) | pending | Inhibrx Biosciences, Inc. INBX | PDUFA April 14, 2027 - Inhibrx Biosciences, Inc. | |
| 2026-11-30 | PDUFA date (company-disclosed) | pending | Cogent Biosciences, Inc. COGT | bezuclastinib | PDUFA November 30, 2026 - Cogent Biosciences, Inc. (bezuclastinib) |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-13 est. | P1/P2 | GlaxoSmithKline | NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Melanoma; Hodgkin Lymphoma; High and Low Grade Glioma; Glioblastoma Multiforme (GBM); Diffuse Intrin | active not recruiting | 83 |
| 2026-10-01 est. | P1/P2 | USWM CT, LLC | NCT05642455 SPEARHEAD-3 Pediatric Study | Synovial Sarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neuroblastoma (NBL); Osteosarcoma | recruiting | 20 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-07-03 est. | P3 | Boehringer Ingelheim | NCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS) | withdrawn | |
| 2026-06-17 | P3 | Hansoh BioMedical R&D Company | NCT06935409 Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure | Osteosarcoma | completed | 122 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06500091 TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | Soft Tissue Sarcoma; Melanoma | not yet recruiting | 54 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-25 | P3 | Polaris Group PII | NCT05712694 Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Soft Tissue Sarcoma | terminated | 218 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "sarcoma"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.